Participants hospitalized with severe COVID-19 (WHO Clinical Progression Scale score 6 to 10), showed significantly higher baseline median levels of all selected biomarkers, except for IFNα, and significantly lower levels of RANTES, compared to controls. The gene discussed is CCL5; the disease is COVID-19.